Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

NCT04093362 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Due to Poor Recruitment

Conditions

Advanced Cholangiocarcinoma
FGFR2 Gene Rearrangements

Interventions

DRUG: Futibatinib
DRUG: Cisplatin
DRUG: Gemcitabine

Sponsor

Taiho Oncology, Inc.